JPMorgan analyst Tessa Romero lowered the firm’s price target on Dyne Therapeutics to $18 from $24 and keeps an Overweight rating on the shares. The analyst says "sufficient caution" is well reflected at current share levels for DYNE-101, which she says is utilizing a new approach via a transferrin 1 receptor-targeted fab to enable the transport of targeted therapeutics into the muscle. Romero’s comparative look at the space together with recent key opinion leader feedback makes her "feel comfortable about where Dyne is positioned vs. others in development."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DYN:
- Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
- Dyne Therapeutics to Present at Investor Conferences in November
- Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
- Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
